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Background: The complex endocrine and exocrine functionality of the human pancreas depends on an efficient
fluid transport through the blood and the lymphatic vascular systems. The lymphatic vasculature has key roles in
the physiology of the pancreas and in regulating the immune response, both important for developing successful
transplantation and cell-replacement therapies to treat diabetes. However, little is known about how the lymphatic and
blood systems develop in humans. Here, we investigated the establishment of these two vascular systems in human
pancreas organogenesis in order to understand neovascularization in the context of emerging regenerative therapies.
Methods: We examined angiogenesis and lymphangiogenesis during human pancreas development between 9 and
22 weeks of gestation (W9-W22) by immunohistochemistry.
Results: As early as W9, the peri-pancreatic mesenchyme was populated by CD31-expressing blood vessels as well as
LYVE1- and PDPN-expressing lymphatic vessels. The appearance of smooth muscle cell-coated blood vessels in the
intra-pancreatic mesenchyme occurred only several weeks later and from W14.5 onwards the islets of Langerhans
also became heavily irrigated by blood vessels. In contrast to blood vessels, LYVE1- and PDPN-expressing
lymphatic vessels were restricted to the peri-pancreatic mesenchyme until later in development (W14.5-W17), and
some of these invading lymphatic vessels contained smooth muscle cells at W17. Interestingly, between W11-W22,
most large caliber lymphatic vessels were lined with a characteristic, discontinuous, collagen type IV-rich basement
membrane. Whilst lymphatic vessels did not directly intrude the islets of Langerhans, three-dimensional reconstruction
revealed that they were present in the vicinity of islets of Langerhans between W17-W22.
Conclusion: Our data suggest that the blood and lymphatic machinery in the human pancreas is in place to support
endocrine function from W17-W22 onwards. Our study provides the first systematic assessment of the progression of
lymphangiogenesis during human pancreatic development.
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Type 1 diabetes is an autoimmune disease that progres-
sively destroys insulin-producing β-cells [1]. Given the
shortage of organ donors, pluripotent stem cells, such as
human embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs), but also adult stem cells
from the pancreas may provide a valuable source of
insulin-producing β-cells for cell-replacement therapies as* Correspondence: lopes@lumc.nl
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unless otherwise stated.well as for studying mechanisms underlying β-cell path-
ologies [2-4]. To date, protocols to differentiate β-cells
from pluripotent stem cells in vitro usually generate
immature endocrine cells that constitutively secrete
insulin, instead of responding to exogenous glucose
levels [5-7]. The maturation of these cells into fully
functional β-cells is only augmented after transplant-
ation into (immunocompromised) mice [8-10] and
likely depends upon a favorable microenvironment for
cell maturation and function.
There are only a few studies addressing human pancreas
development due to the restricted availability of human
embryos [11-20]. Human pancreas development startstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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emergence of dorsal and ventral buds from the foregut
epithelium. At 6 weeks of gestation (equivalent to 4
weeks post conception) the two buds fuse and become a
single organ formed by stratified epithelium embedded
in mesenchyme. The stratified epithelium will give rise
to both the exocrine and endocrine compartments of
the definitive pancreas [21].
One important physiological regulator of development
and normal function of the endocrine cells of the pancreas
is the microcirculation through specialized sinusoidal
capillaries that irrigate the islets of Langerhans [22-24].
The endothelial cells of these capillaries are highly fen-
estrated to facilitate the exchange of signals. The dense
network ensures that each endocrine cell (glucagon-
producing α-cell, insulin-producing β-cell, somatostatin-
producing δ-cell, ghrelin-producing ε-cell and pancreatic
polypeptide-producing PP-cell) is in close proximity to the
circulation [25]. It makes up a considerable part of the
islets and it is responsible for critical communication
via blood signals between the endocrine and exocrine
pancreas and also between the different cell types that
populate the islets. After transplantation of islets to the
pancreas, angiogenesis is key to restoring proper function
[8,25-28].
Another important physiological aspect that regulates
the normal function of the pancreas is the presence of a
lymphatic system [29]. The main function of the lymph-
atic system in the pancreas is to drain excess fluid that can
contain both leaking endocrine hormones and exocrine-
produced digestive enzymes from the interstitial space
[29,30]. Another important function of the lymphatic
system, particularly in the context of transplantation and
cell-replacement therapies, is the ability to facilitate the
immediate transport of immune cells and soluble antigens
from the peripheral tissues to the regional lymph nodes
for an appropriate immune response [31]. However,
understanding the lymphatic vascular network remained
poor due to the lack of specific markers capable of distin-
guishing lymphatic vessels. Two cell surface proteins,
namely lymphatic vessel endothelial hyaluronan receptor
1 (LYVE1) and podoplanin (PDPN), have stimulated
lymphatic vasculature research as they are expressed
specifically by lymphatic endothelial cells, and not blood
endothelial cells [32-34].
Together, the lymphatic and blood vascular system
control pancreas homeostasis, including the transport of
signals, gases, nutrients, hormones, and circulating cells.
Both the blood and the lymphatic, vascular systems are
highly branched tubular networks, in which vessels are
formed by endothelial cells, but there are fundamental
differences in terms of function, morphology, and com-
position [33,35,36]. In contrast to the circular blood
vascular network, the lymphatic system is blind-ended,consisting of both lymphatic capillaries, pre-collecting and
larger collecting lymphatic vessels that are connected
to lymph nodes. A profound understanding of the devel-
opment of the blood and lymphatic vascular system dur-
ing pancreas organogenesis and the interaction between
these systems and human endocrine cells can provide im-
portant information on cell maturation and function both
in vitro and in vivo.
In the human pancreas, the presence of CD34-positive
blood endothelial cells has been observed from 8 weeks
of gestation [13]; PDPN-positive lymphatic vessels have
been reported in the pancreas of a single fetus of 18
weeks of gestation [37] and mentioned briefly in a study
of the anatomy of the mesocolon transversum at 13 and
16 weeks of gestation [38]. However, the timing of
colonization by lymphatic vessels and its relation to the
formation of blood vessels in the pancreas is not known.
We therefore studied the temporal and spatial progression
of lymphangiogenesis and compared this with angiogen-
esis during human pancreas development between 9 and
22 week of gestation.
Methods
Fetal pancreas collection
Fourteen human fetal pancreatic specimens between 9
and 22 weeks of gestation (W9-W12, n = 5; W14-W22,
n = 9) were collected from elective abortion tissue
obtained by vacuum aspiration. “Weeks of gestation”
used in this study is based on the last menstrual period
(LMP), to convert to “weeks post conception” one need
to subtract two weeks. This study was approved by the
Medical Ethics Committee of the Leiden University
Medical Center (protocol 08.087). Informed consent was
obtained on the basis of the Declaration of Helsinki by
the World Medical Association (WMA). All pancreata
were fixed in 4% (w/v) paraformaldehyde (MERCK,
Darmstadt, Germany) in PBS overnight at 4°C. Fixation
was followed by dehydration in ethanol, xylene and
paraffin embedding using standard procedures. Embed-
ding was performed using a Shandon Excelsior tissue
processor (Thermo Scientific, Altrincham, UK).
Histology and immunohistochemistry
Paraffin-embedded tissues were sectioned (5 μm) using a
RM2255 microtome (Leica Microsystems GmbH, Wetzlar,
Germany) and mounted on StarFrost slides (Waldemar
Knittel, Braunschweig, Germany). The sections were
deparaffinized and rehydrated by standard procedures,
namely in xylene and followed by a decreasing series of
ethanol ending by rinsing in distilled water. To assess
the morphology of the pancreatic sections, a Haematoxy-
lin (MERCK, Darmstadt, Germany) and Eosin (MERCK,
Darmstadt, Germany) staining was performed by standard
procedures.
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for antigen retrieval depending on the primary antibodies:
1) 12 minutes at 97°C in 0.01M sodium citrate buffer (pH
6.0) followed by cooling down; 2) 12 minutes at 97°C in
Tris/EDTA buffer (pH 9.0) followed by cooling down; 3)
5-10 minutes 20 μg/ml proteinase K (Promega, Madison,
USA) in TE-CaCl2 buffer (pH8.0) at room temperature
(RT). After antigen retrieval, the sections were blocked
with 1% bovine serum albumin, fraction V (BSA, Sigma-
Aldrich, St. Louis, USA) in phosphate buffered-saline
(PBS) with 0.05% Tween-20 (Promega, Madison, USA) for
1 hour at RT, and incubated with the primary antibodies
diluted in the blocking solution overnight at 4°C in a
humidified chamber. The primary antibodies used in this
study were: Rabbit anti-alpha smooth muscle actin (1:100,
ab5694, Abcam, Cambridge, UK), mouse anti-amylase
(1:100, sc46657, Santa Cruz Biotechnologies, Dallas,
USA), mouse anti-CD31 (1:100, M0823, Dako, Glostrup,
Denmark), mouse anti-CD68 (1:1000, M0814, Dako),
rabbit anti-CK19 (1:250, ab52625, Abcam, Cambridge,
UK), mouse anti-CK19 (ready-to-use, M0888, Dako),
rabbit anti-collagen type IV (1:50, AB748, Millipore,
Bedford, USA), goat anti-endoglin (1:100, BAF1097,
R&D Systems, Minneapolis, USA), rabbit anti-glucagon
(1:200, VP-G806, Vector Laboratories Ltd., Peterborough,
UK), rabbit anti-insulin (1:100, sc-9168, Santa Cruz
Biotechnologies, Dallas, USA), rabbit anti-LYVE1 (1:100,
102-PA50AG, ReliaTech, Braunschweig, Germany) and
mouse anti-podoplanin (1:100, ab77854, Abcam, Cambridge,
UK). The secondary antibodies were diluted in blocking
solution and applied at RT for 1 hour followed by a
nuclear counterstaining with 4′,6-diamidino-2-pheny-
lindole (DAPI, Life Technologies, Carlsbad, USA). The
secondary antibodies used were: Alexa Fluor 488
donkey anti-rabbit (1:500, A21206, Life Technologies,
Carlsbad, USA), Alexa Fluor 594 donkey anti-mouse
(1:500, A-21203, Life Technologies, Carlsbad, USA),
and Alexa Fluor 594 donkey anti-goat (1:500, A-11058,
Life Technologies, Carlsbad, USA). The sections were
then mounted using ProLong Gold (Life Technologies,
Carlsbad, USA). As antibody specificity controls, primary
antibodies were omitted.
Imaging
The sections stained for Haematoxylin and Eosin were
scanned with the Panoramic MIDI digital scanner
(3DHISTECH Ltd., Budapest, Hungary). Selection of
the desired areas and adjustments were performed with
the Panoramic Viewer (3DHISTECH Ltd., Budapest,
Hungary). The immunofluorescence images were acquired
with a Leica DM5500 fluorescence upright microscope
(Leica, Mannheim, Germany) equipped with a Cool
Snap HQ2 CCD camera (Photometrics, Tucson, Arizona,
USA) or a Leica TCS SP8 upright microscope (Leica,Mannheim, Germany) operated with the Leica Application
Suite Advanced Fluorescence software (LAS AF). Bright-
ness and contrast was adjusted either by using ImageJ
(NIH, Bethesda, USA) or Photoshop CS6 (Adobe Systems
Inc., San Jose, USA).
3D-reconstruction
For 3D-reconstruction, serial paraffin transversal sections
(10 μm) of fetal pancreatic specimens at W17 and W21
were immunostained for glucagon and podoplanin as
described in histology and immunohistochemistry. The
sections were digitalized using the Panoramic MIDI
digital scanner (3DHISTECH Ltd., Budapest, Hungary)
and the reconstruction was conducted with the Amira
4.1 software (Visage Imaging, Berlin, Germany).
Results
Peri-pancreatic and intra-pancreatic mesenchyme in the
human fetal pancreas
In this study, we refer to two types of mesenchyme in the
pancreas (Figure 1A): The peri-pancreatic mesenchyme
(PPM) and the intra-pancreatic mesenchyme (IPM). The
PPM is the thin layer of connective tissue surrounding the
pancreas, whereas the IPM is the connective tissue in
which the endocrine and exocrine cells are embedded that
will form the (interlobular) septa defining the lobular
structure of the adult pancreas.
At W9-W12, the developing pancreas contained a
prominent layer of PPM compared to the IPM where
the pancreatic epithelium and ducts localize (Figure 1A,
left panel). At W17-W22, both types of mesenchyme
were less prominent compared to W9-W12, due to the
epithelial expansion that leads to endocrine and exocrine
differentiation (Figure 1A, middle and right panel).
Spatial progression of angiogenesis in the pancreatic
mesenchymal compartments
To investigate angiogenesis, we used an antibody against
CD31 (or PECAM1), an established marker of endothelial
cells [34,39]. From W9-W19, CD31-positive vessels were
observed in both the PPM and IPM (Figure 1B), many
close to CK19-positive pancreatic epithelial cells. To
investigate whether the blood vessels at W9 (the earliest
time point analyzed) resulted from angiogenesis or vascu-
logenesis, we used an antibody against the angiogenic
marker endoglin [40,41]. Already at W9, the blood vessels
in both PPM and IPM were endoglin-positive (Figure 1C),
suggesting that angiogenesis is the main mechanism for
blood vessel formation in the pancreas during the investi-
gated period.
Microcirculation in the islets of Langerhans
Next, we investigated the relationship between the devel-
opment of the endocrine compartment and angiogenesis
Figure 1 Angiogenesis during human pancreatic development. (A) Haematoxylin and eosin (H&E) staining of pancreata at W11, W17 and
W22 illustrating the two types of mesenchyme, the peri-pancreatic mesenchyme (PPM) and intra-pancreatic mesenchyme (IPM). The pancreatic
epithelium is embedded in the IPM. (B) Pancreata at W9, W11 and W19 immunostained for CD31 and CK19. White line in the top panel shows the
separation between the PPM and IPM. White arrows point to CD31-positive blood vessels. (C) Pancreas at W9 immunostained for endoglin (ENG) and
CK19. (D) Pancreata at W12, W19 and W22 immunostained for CD31 and glucagon (GLG, α-cells). Dashed line shows the islet of Langerhans. White
arrows point to capillaries. (E) Pancreata at W12, W14.5, W19 and W21 immunostained for CD31 and insulin (INS, β-cells). Note that autofluorescent red
blood cells, as yellow/orange dots, are present in in all images. Scale bars: (A, left panel) 200 μm, (A, middle and right panel) 1 mm, (B-E) 30 μm.
Roost et al. Vascular Cell 2014, 6:22 Page 4 of 11
http://www.vascularcell.com/content/6/1/22in the developing pancreas. We detected insulin-positive
and glucagon-positive endocrine cells within the pancre-
atic epithelium as early as W9 (data not shown). At W11,the glucagon-positive endocrine cells resided primarily as
single cells within the pancreatic epithelium, whereas
the insulin-positive endocrine cells already formed small
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At W12-W22, the endocrine compartment of the pancreas
developed to form the islets of Langerhans, with the typical
core-mantle morphology, with glucagon-producing α-cells
forming the mantle (Figure 1D) and insulin-producing β-
cells forming a compact core (Figure 1E) as described
[13,20]. Interestingly, a network of CD31-positive capillaries
was visible in proximity of the small glucagon-positive and
insulin-positive cell clusters around W12 and penetrating
the islets, forming the islet microcirculation, at W14.5-W22
(Figure 1D and E). Our observations suggest that at least by
W22 the islets of Langerhans and their microcirculation
may form a physiological functional unit (Figure 1D,
right panel).
Association of the blood vasculature with smooth muscle
cells in the developing human pancreas
A key step in the maturation of the endothelial tubes
to form arteries during vascular development is the
attraction of mural cells and their subsequent differen-
tiation to smooth muscle cells through endothelial cell
association [42,43]. The association of smooth muscle
cells, expressing alpha smooth muscle actin (ACTA2),
with the blood vessels (arteries) was observed as early
as W9 (Figure 2A, left panels), but only in the PPM
(Figure 2A, left panels). However, from W12 onwards
the CD31-positive blood vessels in the IPM also started
to show association with ACTA2-positive smooth muscle
cells (Figure 2A, middle panels). From W12-W22, the
number of CD31-positive blood vessels associated with
ACTA2-positive cells, presumably arteries, increased both
in the IPM and PPM (Figure 2A, right panels), but some
of the large caliber CD31-positive vessels, presumably
veins, remained devoid of smooth muscle cells. Large
caliber blood vessels (uncoated or coated with ACTA2-
positive smooth muscle cells) were never observed in
close association with islets of Langerhans. Concluding,
the association of smooth muscle cells with blood vessels
showed a clear spatial developmental delay of several
weeks between the IPM and PPM. By contrast, at W9
blood vessels containing a collagen type IV (COL4A)-rich
basement membrane, another key step in the vascular
maturation, was already clearly visible in both PPM and
IPM (Figure 2B).
Lymphangiogenesis in the pancreatic mesenchymal
compartments
From W9 to about W14.5-W17, LYVE1-positive and
PDPN-positive small lymphatic vessels were present
exclusively in the PPM (Figure 3A and B, white arrows).
However, LYVE1, but not PDPN, is also known to be
expressed by both CD68-positive and F4/80-positive
macrophages [44-46], and those were present as CD68-
positive and LYVE1-positive single cells in both thePPM and IPM throughout development (Additional
file 1: Figure S1A). By W17, LYVE1-positive and PDPN-
positive lymphatic larger caliber vessels were visible in
both the PPM and IPM (Figure 3C and D, white arrows),
but were rarely or not observed penetrating the intra-
lobular region containing the epithelial-derived tissue
(the developing acinar or ductal structures and the
islets of Langerhans). The first few amylase-positive
acinar cells were observed at W14.5 (Additional file 1:
Figure S1B), the stage when lymphatic vessels start to
colonize the IPM. However, we did not observe any
direct association of lymphatic vessels with amylase-
positive cells until W22 either (Additional file 1:
Figure S1B).
Even though there is no direct penetration, from
3D-reconstructions, we observed multiple lymphatic
capillaries in close vicinity of islets of Langerhans, at
least between W17-W21 (Figure 4A and B; Additional
files 2 and 3: Figure S2 and S3). In summary, we observed
both lymphatic and blood vessels in the PPM at W9.
However, colonization of the IPM by lymphatic vessels
(W14.5-W17) was delayed by several weeks compared
to the colonization by blood vessels (W9-W11) and was
excluded from the islets of Langerhans.
Association with smooth muscle cells and basement
membrane formation in the lymphatic vasculature
During maturation and remodeling of the lymphatic
network, much like the blood vascular network, ACTA2-
positive smooth muscle cells are recruited to coat the
pre-collecting lymphatics rather sparsely and the col-
lecting lymphatics more densely [47,48]. In contrast to
the association of the blood vascular network with smooth
muscle cells observed at W9 in the PPM, the association
of ACTA2-positive smooth muscle cells with the PDPN-
positive lymphatic vessels was observed only at about
W14.5 (Figure 5A), even though both lymph and blood
vessels were present in the PPM from W9. In the IPM, the
association of lymphatic vessels with smooth muscle cells
occurred at about W17, where the largest PDPN-positive
lymphatic vessels were only sparsely covered with smooth
muscle cells (Figure 5A).
Next, we analyzed the expression of collagen type IV
(COL4A), a component of the vascular basement mem-
brane, but also a good indicator of maturation of the
lymphatic vessels. COL4A forms a continuous basement
membrane in all types of blood vessels and collecting
lymphatic vessels, but it forms a discontinuous basement
membrane in pre-collecting lymph vessels and does not
form any basement membrane in the lymph capillaries
[47,49-52]. By W11, larger-caliber PDPN-positive lymph-
atic vessels in the PPM showed a discontinuous
COL4A-positive basement membrane (Figure 5B, left
panel). In the IPM, the invasion by the lymphatic vessels
Figure 2 Blood vessels and their association with smooth muscle cells and basement membrane formation during human pancreatic
development. (A) Pancreata at W9, W11, W12 and W19 immunostained for CD31 and smooth muscle actin (ACTA2). Smooth muscle cell association
with blood vessels in the peri-pancreatic mesenchyme (PPM, top panels) and intra-pancreatic mesenchyme (IPM, bottom panels) is shown. (B) Pancreas at
W9 immunostained for CD31 and collagen type IV (COL4A) illustrating blood vessels in the PPM (top panels) and IPM (bottom panels). White arrows point
to CD31-positive blood vessels with a continuous basement membrane. Note that autofluorescent red blood cells, as yellow/orange dots, are present in in
all images. Scale bars: 30 μm.
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with the appearance of a discontinuous COL4A-positive
basement membrane (about W17) (Figure 5B, middle
and right panels). This discontinuous COL4A-positive
basement membrane was maintained at least until W22
in both the PPM and IPM. Together, our data suggestthat between W9-W22 there are only lymph capillaries
and pre-collecting lymphatic vessels and no collecting
lymphatic vessels in the pancreas.
During pancreas development, lymphangiogenesis oc-
curred rather gradually in the PPM, with invasion at
W9, deposition of basement membrane around W11
Figure 3 Lymphangiogenesis during human pancreatic development. (A) Pancreas at W9 immunostained for CK19 and LYVE1. White arrows
point to LYVE1-positive lymphatic vessels. White line shows the separation between the peri-pancreatic mesenchyme (PPM) and intra-pancreatic
mesenchyme (IPM). (B) Pancreas at W11 immunostained for CK19 and podoplanin (PDPN). White arrows point to PDPN-positive lymphatic vessels.
(C) Pancreata at W14.5, W17, W19 and W21 immunostained for CK19 and LYVE1. (D) Pancreata at W14.5, W17, W19 and W21 immunostained for
CK19 and PDPN. Note that autofluorescent red blood cells, as yellow/orange dots, are present in in all images. Scale bars: 50 μm.
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IPM, however, all steps occurred almost simultaneously
within 3 weeks, between W14.5-W17 (Figure 6).
Discussion
Our study showed that in the developing human pan-
creas, angiogenesis precedes lymphangiogenesis both inthe PPM and the IPM (Figure 6). In fact, by W9, mature
smooth muscle cell-coated blood vessels were already
observed in the PPM, whereas sparsely smooth muscle
cell-coated lymph vessels were only observed there by
W14.5 (a delay of about 6 weeks). In the IPM, we
pinpointed the difference in timing of association with
smooth muscle cells to be approximately 5 weeks (W12
Figure 4 Spatial arrangement of lymphatic vessels and islets
of Langerhans during human pancreatic development. (A, B)
Three-dimensional reconstructions of islets of Langerhans at W17
(A) and W21 (B), showing them from two different rotation angles.
The mantle of glucagon (GLG)-positive α-cells and the GLG-negative
core of the islets of Langerhans are depicted in green and blue,
respectively. PDPN-positive lymphatic vessels are colored red and large
ducts, identified by their morphology only, are represented in yellow.
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that the processes of angiogenesis and lymphangiogen-
esis followed independent developmental paths both
temporally and spatially, which may perhaps be correlated
with the development of the endocrine and exocrine
compartments between W9-W22. Up to W22, we did
not observe any PDPN-positive lymphatic vessels with
a continuous layer of smooth muscle cells or a continuous
COL4A-positive basement membrane, indicating that the
formation of collecting lymphatic vessels may occur only
later in development in the pancreas.We observed proximity between CD31-positive blood
vessels and small clusters of glucagon-positive and
insulin-positive at (W)12 weeks of gestation (equivalent
to 10 weeks post conception) in agreement with Piper
and colleagues (2004) that reported proximity between
CD34-positive blood vessels at 10.5 weeks post concep-
tion [13]. However, the following developmental stage
analyzed by Piper and colleagues (2004) was week 14 post
conception (equivalent to (W)16 weeks of gestation) when
they observed CD34-positive blood vessels penetrating
bona fide islets of Langerhans [13]. We now report pene-
tration of the first islets of Langerhans by CD31-positive
blood vessels at (W) 14.5 weeks of gestation (equivalent to
12.5 weeks post conception). Furthermore, the immediate
establishment of an extensive microvasculature in the
islets of Langerhans while these are still being formed
confirms the importance of blood vessels as integral part
of the islets of Langerhans.
The islets of Langerhans were not directly invaded by
lymphatic vessels, but these vessels were clearly present
in the IPM in the vicinity of islets by W17. In aggree-
ment, in adult pancreas lymphatic vessels have also been
observed not only in the interlobular connective tissue,
but also intralobularly where the islets of Langerhans
reside [53], suggesting some degree of proximity between
lymphatics and islets as in the fetal pancreas. Even though
the functionality of fetal islets of Langerhans regarding
insulin release in response to glucose by W22 is still a
matter of debate [54-57], the vascular machinery to support
an insulin-glucose response by the islet of Langerhans
seems to be in place.
On the overall morphology of the islets of Langerhans,
we report that by W12 the majority of the developing islets
of Langerhans exhibited a single core-mantle structure
showing a characteristic compact core of insulin-producing
β-cells partially surrounded by a thick mantle of glucagon-
producing α-cells in agreement with others [13,20].
However, in contrast to Jeon and colleagues (2009) that
observed a predominantly homotypic character in the
islets of Langerhans between W18-W21, we observed
that the single core-mantle structure was maintained.
From the two lymphatic endothelial cell-specific anti-
bodies used, PDPN is expressed by all lymphatic vessels,
whereas LYVE1 is expressed by capillaries and pre-
collecting lymphatic vessels, but not by the collecting
lymphatic vessels [32,48,58], restricting its utility to early
stages of lymphangiogenesis. Moreover, we observed that
LYVE1, but not PDPN, is also expressed by CD68-positive
macrophages as previously described [44-46]. Interestingly,
it has been proposed that perhaps these LYVE1-positive
macrophages could represent lymphendothelial progenitors
[59,60]. Combining the use of both LYVE1 and PDPN to
mark lymphatic vessels provided a robust assessment of
lymphangiogenesis in the developing human pancreas.
Figure 5 Association of lymphatic vessels with smooth muscle cells and basement membrane formation during human pancreatic
development. (A) Pancreata at W12, W14.5 and W17 immunostained for podoplanin (PDPN) and smooth muscle actin (ACTA2). PDPN-positive
lymphatic vessels (white arrows) showed no association with smooth muscle cells up to W12 in contrast to arteries (white asterisks). From W14.5
onwards, PDPN-positive lymphatic vessels (white arrow) were sparsely covered with smooth muscle cells. (B) Pancreata at W11 and W17 immunostained
for PDPN and COL4A. PDPN-positive lymphatic vessels (white arrows) were covered with a discontinuous basement membrane, whereas blood vessels
(white asterisks) were covered by a continuous basement membrane. Scale bars: 30 μm.
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We report here the first systematic study investigating
the progression of lymphangiogenesis and angiogenesis
between W9 and W22 of human pancreas development
(Figure 6). We show that both processes have their own
dynamics of invasion and maturation, but both seem
in place to provide a functional response by W22.Figure 6 Model of the progression of lymphangiogenesis and angiog
the progression of lymphangiogenesis (top) and angiogenesis (bottom) sh
membrane (BM) and the association with smooth muscle cells (SMCs) in the
(IPM) between W9 and W22.Understanding the establishment of the two vascular
systems during normal human pancreas development
is of great interest to develop better protocols for
transplantation of islets of Langerhans, as well as to
optimize the molecular niche necessary for the differ-
entiation of pluripotent stem cells to insulin-producing
β-cells.enesis during human pancreatic development. Cartoon illustrating
owing the timing of invasion, formation of a COL4A-rich basement
peri-pancreatic mesenchyme (PPM) and intra-pancreatic mesenchyme
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Additional file 1: Figure S1. LYVE1-positive macrophages and exocrine
differentiation during human pancreas development. (A) Pancreata at W9
and W17 immunostained for LYVE1 and CD68, a marker to identify cells of
the macrophage lineage (white arrows) in the peri-pancreatic mesenchyme
(PPM; top panels) and intra-pancreatic mesenchyme (IPM; bottom panels).
(B) Pancreata at W12, W14.5, W17 and W19 stained for amylase (AMY) and
LYVE1. Scale bars: (A) 30 μm, (B) 50 μm.
Additional file 2: Figure S2. Spatial arrangement of lymphatic vessels
and islets of Langerhans in a W17 human pancreas. Consecutive sections
of a W17 pancreas immunostained for PDPN and glucagon (GLG, α-cells)
used for the 3D-reconstruction in Figure 4A.
Additional file 3: Figure S3. Spatial arrangement of lymphatic vessels
and islets of Langerhans in a W21 human pancreas. Consecutive sections
of a W21 pancreas immunostained for PDPN and glucagon (GLG, α-cells)
used for the 3D-reconstruction in Figure 4B.
Abbreviations
ACTA2: Alpha smooth muscle actin; BM: Basement membrane;
CK19: Cytokeratin 19; COL4A: Collagen type IV; GLG: Glucagon;
H&E: Haematoxylin and eosin; INS: Insulin; IPM: Intra-pancreatic mesenchyme;
hESCs: Human embryonic stem cells; hiPSCs: Human induced pluripotent
stem cells; LYVE1: Lymphatic vessel endothelial hyaluronan receptor 1;
PDPN: Podoplanin; PPM: Peri-pancreatic mesenchyme; SMC: Smooth muscle
cell; RT: Room temperature.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MSR designed and performed experiments, analyzed the data and wrote the
manuscript. LvI performed experiments. AdMB performed the 3D-reconstruction.
SMCdSL, CLM, FC and EJPdK designed the experiments, analyzed the
data and wrote the manuscript. All authors read and approved the
final manuscript.
Acknowledgments
This work was supported by the Netherlands organization of Scientific Research
(NWO) [ASPASIA 015.007.037] and the Interuniversity Attraction Poles-Phase VII
[IUAP/PAI P7/14] to SMCdSL, the Bontius Stichting [PANCREAS] to MSR, FC,
CLM, EJPdK, Stichting DON to EJPdK, and the Fundação para a Ciência e
Tecnologia (FCT) [SFRH/BD/94387/2013] to AdMB.
We would like to thank the Center for Contraception, Sexuality and Abortion
(CASA) in Leiden and The Hague for collecting the human fetuses; K. Sprenkels,
S. Anjie and I. Navarro for technical support with histology; J. Wiegant and
A.M. van der Laan for technical support with microscopy; M. Heeren and H.
Locher for advice regarding immunofluorescence; L.J.A.C. Hawinkels for the
anti-endoglin antibody; and A.C. Kraima for the fruitful discussions on the
lymphatic vascular system.
Author details
1Department of Anatomy and Embryology, Leiden University Medical Center,
Einthovenweg 20, 2333 ZC Leiden, The Netherlands. 2Department of
Nephrology, Leiden University Medical Center, Albinusdreef 2, 2300 RC
Leiden, The Netherlands. 3Hubrecht Institute for Developmental Biology and
Stem Cell Research, University Medical Center, Uppsalalaan 8, 3584 CT
Utrecht, The Netherlands. 4Department for Reproductive Medicine, Ghent
University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Received: 26 June 2014 Accepted: 26 September 2014
Published: 1 November 2014
References
1. Bluestone JA, Herold K, Eisenbarth G: Genetics, pathogenesis and clinical
interventions in type 1 diabetes. Nature 2010, 464:1293–1300.
2. Halban PA, German MS, Kahn SE, Weir GC: Current status of islet cell
replacement and regeneration therapy. J Clin Endocrinol Metab 2010,
95:1034–1043.3. Weir GC, Cavelti-Weder C, Bonner-Weir S: Stem cell approaches for
diabetes: towards beta cell replacement. Genome Med 2011, 3:61.
4. Carlotti F, Zaldumbide A, Ellenbroek JH, Spijker HS, Hoeben RC, de Koning EJ:
Beta-cell generation: can rodent studies be translated to humans?
J Transplant 2011, 2011:892453.
5. D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG,
Moorman MA, Kroon E, Carpenter MK, Baetge EE: Production of pancreatic
hormone-expressing endocrine cells from human embryonic stem cells.
Nat Biotechnol 2006, 24:1392–1401.
6. Wei R, Yang J, Hou W, Liu G, Gao M, Zhang L, Wang H, Mao G, Gao H,
Chen G, Hong T: Insulin-producing cells derived from human embryonic
stem cells: comparison of definitive endoderm- and nestin-positive
progenitor-based differentiation strategies. PLoS One 2013, 8:e72513.
7. Wei R, Yang J, Liu GQ, Gao MJ, Hou WF, Zhang L, Gao HW, Liu Y, Chen GA,
Hong TP: Dynamic expression of microRNAs during the differentiation of
human embryonic stem cells into insulin-producing cells. Gene 2013,
518:246–255.
8. Hayek A, Beattie GM: Processing, storage and experimental transplantation
of human fetal pancreatic cells. Ann Transplant 1997, 2:46–54.
9. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H,
Richardson M, Smart NG, Cunningham J, Agulnick AD, D’Amour KA,
Carpenter MK, Baetge EE: Pancreatic endoderm derived from human
embryonic stem cells generates glucose-responsive insulin-secreting
cells in vivo. Nat Biotechnol 2008, 26:443–452.
10. Rezania A, Bruin JE, Riedel MJ, Mojibian M, Asadi A, Xu J, Gauvin R, Narayan K,
Karanu F, O’Neil JJ, Ao Z, Warnock GL, Kieffer TJ: Maturation of human
embryonic stem cell-derived pancreatic progenitors into functional islets
capable of treating pre-existing diabetes in mice. Diabetes 2012, 61:2016–2029.
11. Polak M, Bouchareb-Banaei L, Scharfmann R, Czernichow P: Early pattern of
differentiation in the human pancreas. Diabetes 2000, 49:225–232.
12. Piper K, Ball SG, Keeling JW, Mansoor S, Wilson DI, Hanley NA: Novel SOX9
expression during human pancreas development correlates to
abnormalities in Campomelic dysplasia. Mech Dev 2002, 116:223–226.
13. Piper K, Brickwood S, Turnpenny LW, Cameron IT, Ball SG, Wilson DI, Hanley
NA: Beta cell differentiation during early human pancreas development.
J Endocrinol 2004, 181:11–23.
14. Wang R, Li J, Lyte K, Yashpal NK, Fellows F, Goodyer CG: Role for beta1
integrin and its associated alpha3, alpha5, and alpha6 subunits in
development of the human fetal pancreas. Diabetes 2005, 54:2080–2089.
15. Lyttle BM, Li J, Krishnamurthy M, Fellows F, Wheeler MB, Goodyer CG, Wang
R: Transcription factor expression in the developing human fetal
endocrine pancreas. Diabetologia 2008, 51:1169–1180.
16. Sarkar SA, Kobberup S, Wong R, Lopez AD, Quayum N, Still T, Kutchma A,
Jensen JN, Gianani R, Beattie GM, Jensen J, Hayek A, Hutton JC: Global
gene expression profiling and histochemical analysis of the developing
human fetal pancreas. Diabetologia 2008, 51:285–297.
17. Gregg BE, Moore PC, Demozay D, Hall BA, Li M, Husain A, Wright AJ,
Atkinson MA, Rhodes CJ: Formation of a human beta-cell population
within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012,
97:3197–3206.
18. Riedel MJ, Asadi A, Wang R, Ao Z, Warnock GL, Kieffer TJ:
Immunohistochemical characterisation of cells co-producing insulin and
glucagon in the developing human pancreas. Diabetologia 2012, 55:372–381.
19. Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ,
Blaylock J, Piper Hanley K, Hanley NA: Development of the human pancreas
from foregut to endocrine commitment. Diabetes 2013, 62:3514–3522.
20. Jeon J, Correa-Medina M, Ricordi C, Edlund H, Diez JA: Endocrine cell
clustering during human pancreas development. J Histochem Cytochem
2009, 57:811–824.
21. Pan FC, Wright C: Pancreas organogenesis: from bud to plexus to gland.
Dev Dyn 2011, 240:530–565.
22. Ballian N, Brunicardi FC: Islet vasculature as a regulator of endocrine
pancreas function. World J Surg 2007, 31:705–714.
23. Lammert E, Cleaver O, Melton D: Induction of pancreatic differentiation by
signals from blood vessels. Science 2001, 294:564–567.
24. Lammert E, Gu G, McLaughlin M, Brown D, Brekken R, Murtaugh LC, Gerber
HP, Ferrara N, Melton DA: Role of VEGF-A in vascularization of pancreatic
islets. Curr Biol 2003, 13:1070–1074.
25. Lukinius A, Jansson L, Korsgren O: Ultrastructural evidence for blood
microvessels devoid of an endothelial cell lining in transplanted
pancreatic islets. Am J Pathol 1995, 146:429–435.
Roost et al. Vascular Cell 2014, 6:22 Page 11 of 11
http://www.vascularcell.com/content/6/1/2226. Jansson L, Carlsson PO: Graft vascular function after transplantation of
pancreatic islets. Diabetologia 2002, 45:749–763.
27. Brissova M, Fowler M, Wiebe P, Shostak A, Shiota M, Radhika A, Lin PC,
Gannon M, Powers AC: Intraislet endothelial cells contribute to
revascularization of transplanted pancreatic islets. Diabetes 2004,
53:1318–1325.
28. Cantaluppi V, Biancone L, Figliolini F, Beltramo S, Medica D, Deregibus MC,
Galimi F, Romagnoli R, Salizzoni M, Tetta C, Segoloni GP, Camussi G:
Microvesicles derived from endothelial progenitor cells enhance
neoangiogenesis of human pancreatic islets. Cell Transplant 2012,
21:1305–1320.
29. O’Morchoe CC: Lymphatic system of the pancreas. Microsc Res Tech 1997,
37:456–477.
30. Rasio EA, Hampers CL, Soeldner JS, Cahill GF Jr: Diffusion of glucose,
insulin, inulin, and Evans blue protein into thoracic duct lymph of man.
J Clin Invest 1967, 46:903–910.
31. Girard JP, Moussion C, Forster R: HEVs, lymphatics and homeostatic immune
cell trafficking in lymph nodes. Nat Rev Immunol 2012, 12:762–773.
32. Jackson DG: The lymphatics revisited: new perspectives from the
hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003, 13:1–7.
33. Jurisic G, Detmar M: Lymphatic endothelium in health and disease.
Cell Tissue Res 2009, 335:97–108.
34. Ordonez NG: Immunohistochemical endothelial markers: a review.
Adv Anat Pathol 2012, 19:281–295.
35. Adams RH, Alitalo K: Molecular regulation of angiogenesis and
lymphangiogenesis. Nat Rev Mol Cell Biol 2007, 8:464–478.
36. Choi I, Lee S, Hong YK: The new era of the lymphatic system: no longer
secondary to the blood vascular system. Cold Spring Harb Perspect Med
2012, 2:a006445.
37. Jin ZW, Nakamura T, Yu HC, Kimura W, Murakami G, Cho BH: Fetal anatomy
of peripheral lymphatic vessels: a D2-40 immunohistochemical study
using an 18-week human fetus (CRL 155 mm). J Anat 2010, 216:671–682.
38. Jeong YJ, Cho BH, Kinugasa Y, Song CH, Hirai I, Kimura W, Fujimiya M,
Murakami G: Fetal topohistology of the mesocolon transversum with
special reference to fusion with other mesenteries and fasciae. Clin Anat
2009, 22:716–729.
39. Pusztaszeri MP, Seelentag W, Bosman FT: Immunohistochemical expression
of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in
normal human tissues. J Histochem Cytochem 2006, 54:385–395.
40. ten Dijke P, Goumans MJ, Pardali E: Endoglin in angiogenesis and vascular
diseases. Angiogenesis 2008, 11:79–89.
41. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB,
Wendel DP: Defective angiogenesis in mice lacking endoglin. Science
1999, 284:1534–1537.
42. Folkman J, D’Amore PA: Blood vessel formation: what is its molecular
basis? Cell 1996, 87:1153–1155.
43. Wu J, Bohanan CS, Neumann JC, Lingrel JB: KLF2 transcription factor
modulates blood vessel maturation through smooth muscle cell
migration. J Biol Chem 2008, 283:3942–3950.
44. Attout T, Hoerauf A, Denece G, Debrah AY, Marfo-Debrekyei Y, Boussinesq M,
Wanji S, Martinez V, Mand S, Adjei O, Bain O, Specht S, Martin C: Lymphatic
vascularisation and involvement of Lyve-1+ macrophages in the human
onchocerca nodule. PLoS One 2009, 4:e8234.
45. Harvey NL, Gordon EJ: Deciphering the roles of macrophages in
developmental and inflammation stimulated lymphangiogenesis.
Vasc Cell 2012, 4:15.
46. Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA, Cursiefen C: The
normal human choroid is endowed with a significant number of
lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive
macrophages. Invest Ophthalmol Vis Sci 2008, 49:5222–5229.
47. Paupert J, Sounni NE, Noel A: Lymphangiogenesis in post-natal tissue
remodeling: lymphatic endothelial cell connection with its environment.
Mol Aspects Med 2011, 32:146–158.
48. Maby-El Hajjami H, Petrova TV: Developmental and pathological
lymphangiogenesis: from models to human disease. Histochem Cell Biol
2008, 130:1063–1078.
49. Tammela T, Alitalo K: Lymphangiogenesis: Molecular mechanisms and
future promise. Cell 2010, 140:460–476.
50. Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K:
Immunoelectron microscopic characterization of human dermal
lymphatic microvascular endothelial cells. Differential expression ofCD31, CD34, and type IV collagen with lymphatic endothelial cells vs
blood capillary endothelial cells in normal human skin, lymphangioma,
and hemangioma in situ. J Histochem Cytochem 1998, 46:165–176.
51. Lutter S, Xie S, Tatin F, Makinen T: Smooth muscle-endothelial cell
communication activates Reelin signaling and regulates lymphatic vessel
formation. J Cell Biol 2012, 197:837–849.
52. Norrmen C, Ivanov KI, Cheng J, Zangger N, Delorenzi M, Jaquet M, Miura N,
Puolakkainen P, Horsley V, Hu J, Augustin HG, Ylä-Herttuala S, Alitalo K,
Petrova TV: FOXC2 controls formation and maturation of lymphatic
collecting vessels through cooperation with NFATc1. J Cell Biol 2009,
185:439–457.
53. Rubbia-Brandt L, Terris B, Giostra E, Dousset B, Morel P, Pepper MS:
Lymphatic vessel density and vascular endothelial growth factor-C
expression correlate with malignant behavior in human pancreatic
endocrine tumors. Clin Cancer Res 2004, 10:6919–6928.
54. Ashworth MA, Leach FN, Milner RD: Development of insulin secretion in
the human fetus. Arch Dis Child 1973, 48:151–152.
55. Hoffman L, Mandel TE, Carter WM, Koulmanda M, Martin FI: Insulin secretion
by fetal human pancreas in organ culture. Diabetologia 1982, 23:426–430.
56. Milner RD, Ashworth MA, Barson AJ: Insulin release from human foetal
pancreas in response to glucose, leucine and arginine. J Endocrinol 1972,
52:497–505.
57. Otonkoski T, Andersson S, Knip M, Simell O: Maturation of insulin response
to glucose during human fetal and neonatal development. Studies with
perifusion of pancreatic isletlike cell clusters. Diabetes 1988, 37:286–291.
58. Makinen T, Norrmen C, Petrova TV: Molecular mechanisms of lymphatic
vascular development. Cell Mol Life Sci 2007, 64:1915–1929.
59. Buttler K, Ezaki T, Wilting J: Proliferating mesodermal cells in murine
embryos exhibiting macrophage and lymphendothelial characteristics.
BMC Dev Biol 2008, 8:43.
60. Buttler K, Kreysing A, von Kaisenberg CS, Schweigerer L, Gale N, Papoutsi M,
Wilting J: Mesenchymal cells with leukocyte and lymphendothelial
characteristics in murine embryos. Dev Dyn 2006, 235:1554–1562.
doi:10.1186/2045-824X-6-22
Cite this article as: Roost et al.: Lymphangiogenesis and angiogenesis
during human fetal pancreas development. Vascular Cell 2014 6:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
